BT563 significantly decreases sIL-2R plasma levels despite acute allograft rejection.
Mueller
A R
AR
Department of Surgery, Virchow Clinic, Humboldt University of Berlin, Germany.
Platz
K P
KP
Steinmüller
T
T
Nüssler
N
N
Neumann
U
U
Gerlach
H
H
Stoll
C
C
Bechstein
W O
WO
Neuhaus
P
P
D000206:Actuarial Analysis; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use; D016903:Drug Monitoring; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood / Q000276:immunology* / Q000401:mortality; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012086:Reoperation; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D016572:Cyclosporine; C079843:inolimomab